Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Cash & Equivalents data on file, last reported at $63.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 28.87% year-over-year to $63.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.8 million (down 28.87% YoY) and the FY2025 annual result came in at $116.7 million, down 2.49% from the prior year.
• Cash & Equivalents slipped to $63.8 million in Q1 2026 per CSTL's latest filing, from $116.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $309.0 million in Q1 2022, with the low at $63.8 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $121.3 million, with a median of $95.9 million recorded in 2023.
• Year-over-year, Cash & Equivalents tumbled 64.89% in 2023 and rose 21.11% in 2024.
• Castle Biosciences' Cash & Equivalents stood at $122.9 million in 2022, then fell by 19.61% to $98.8 million in 2023, then grew by 21.11% to $119.7 million in 2024, then dropped by 2.49% to $116.7 million in 2025, then sank by 45.34% to $63.8 million in 2026.
• Business Quant data shows CSTL's Cash & Equivalents at $63.8 million in Q1 2026, $116.7 million in Q4 2025, and $85.6 million in Q3 2025.